Accutar Biotech - also known as AccutarBio - is a company that develops a drug discovery artificial intelligence platform. It was founded in 2015 by Jie Fan, Ke Liu. It is headquartered in Shanghai, China, and maintains an additional office in New York City, United States. The company has received funding from IDG Capital, Yitu Technology, and ZhenFund.
Accutar Biotech's AI is made up of several components: Accutar Virtual Screen, Docking, Intelligent-SAR, and Chemi-Net. These integrated components are used to design novel drug compounds and are intended to be used during the drug development and preclinical trial phases. The virtual representation of protein-ligand bindings is conducted through Accular Virtual Screen and Docking. Intelligent-SAR generates novel compounds which are then validated through co-crystallization and binding assays. Its Chemi-Net platform uses a deep neural network to predict absorption, distribution, metabolism, and excretion (ADME) of these compounds.
AccutarBio Advances AI in Drug Discovery - SyncedReview - Medium
May 1, 2018
Chemi-net: a graph convolutional network for accurate drug property prediction
Ke Liu, Xiangyan Sun, Lei Jia, Jun Ma, Haoming Xing, Junqiu Wu, Hua Gao, Yax Sun, Florian Boulnois, Jie Fan
March 16, 2018